Feng Gang, Li Guorong, Gentil-Perret Anne, Tostain Jacques, Genin Christian
Clinical Immunology Laboratory, North Hospital, CHU of Saint-Etienne, France.
Anticancer Res. 2008 Jan-Feb;28(1A):321-6.
Reliable serum biomarkers for differential diagnosis of conventional renal cell carcinoma (RCC) are highly desirable. Recent studies have confirmed the stability of circulating RNA in serum of cancer patients. The purpose of our study was to evaluate whether the amounts of circulating RNA could discriminate between conventional renal cancer patients and healthy individuals as a tumor marker.
A total of 71 patients with conventional RCC, 12 with renal oncocytomas and 44 healthy individuals entered into this study. Serum samples were taken and subjected to RNA extraction. The amount of RNA was quantified spectrophotometrically. Additionally, 9 serum samples from conventional RCC were also studied one week after nephrectomy. Diagnostic performance of RNA concentration was calculated through the receiver operating characteristic (ROC) curve to distinguish between conventional RCC and healthy individuals.
The mean level of RNA in conventional RCC (1414.19 +/- 91.95 ng/ml) was significantly higher than that in healthy individuals (520.49 +/- 39.75 ng/ml, p<0.0001) and these with renal oncocytomas (560.71 +/- 69.54 ng/ml, p<0.0001). Among the conventional RCC, there was no significant difference in circulating RNA levels in terms of tumor stage, grade or size. The area under the ROC curve was 0.956 (95% confidence interval, 0.923 to 0.989), indicating an acceptable sensitivity and specificity as a tumor marker. For conventional RCC, the RNA level was reduced significantly (p<0.0001) one week after nephrectomy.
The data suggest that elevated circulating RNA may be a valuable diagnostic tool for discriminating conventional RCC patients from normal individuals or from these with renal oncocytoma. Elevated serum circulating RNA provides a new research area as biomarker for the diagnosis of conventional RCC.
非常需要用于鉴别诊断传统肾细胞癌(RCC)的可靠血清生物标志物。最近的研究证实了癌症患者血清中循环RNA的稳定性。我们研究的目的是评估循环RNA的量是否可作为一种肿瘤标志物来区分传统肾癌患者和健康个体。
共有71例传统RCC患者、12例肾嗜酸细胞瘤患者和44名健康个体纳入本研究。采集血清样本并进行RNA提取。用分光光度法定量RNA的量。此外,还对9例传统RCC患者肾切除术后一周的血清样本进行了研究。通过受试者工作特征(ROC)曲线计算RNA浓度的诊断性能,以区分传统RCC患者和健康个体。
传统RCC患者的RNA平均水平(1414.19±91.95 ng/ml)显著高于健康个体(520.49±39.75 ng/ml,p<0.0001)和肾嗜酸细胞瘤患者(560.71±69.54 ng/ml,p<0.0001)。在传统RCC患者中,循环RNA水平在肿瘤分期、分级或大小方面无显著差异。ROC曲线下面积为0.956(95%置信区间,0.923至0.989),表明作为一种肿瘤标志物具有可接受的敏感性和特异性。对于传统RCC患者,肾切除术后一周RNA水平显著降低(p<0.0001)。
数据表明,循环RNA升高可能是区分传统RCC患者与正常个体或肾嗜酸细胞瘤患者的一种有价值的诊断工具。血清循环RNA升高为传统RCC的诊断提供了一个作为生物标志物的新研究领域。